Recombinant polyclonal proteins targeting hepatitis b virus (hbv) and methods of use thereof
AssigneeGigaGen, Inc.
InventorsAdam Shultz ADLER, Sheila KEATING, Rena Aviva MIZRAHI, Ashley Kristine GRAS, Michael ASENSIO
Life of this patent
Estimating the term…
Abstract
Provided herein are pharmaceutical compositions comprising recombinant polyclonal antibodies for treatment of hepatitis B. Specifically, recombinant polyclonal antibodies specific to HBV antigens are provided. Also provided are the methods of making a pharmaceutical composition comprising the recombinant polyclonal antibodies.
Claims37
A pharmaceutical composition comprising a library of antigen-binding proteins (ABPs), wherein the library comprises (i) at least 100 ABPs specifically binding to a Hepatitis B virus (HBV) surface antigen and (ii) a pharmaceutically acceptable excipient, wherein each of the ABPs comprises a cognate pair of heavy chain and light chain variable regions from a single cell out of a blood sample from a donor previously vaccinated with an HBV vaccine;
- and has been generated from a polynucleotide construct encoding the cognate pair of heavy chain and light chain variable regions.
(canceled)
6-9. (canceled)
11-15. (canceled)
17-18. (canceled)
20-21. (canceled)
23-25. (canceled)
(canceled)
32-41. (canceled)
43-44. (canceled)
46-57. (canceled)
A method of making antigen-binding proteins (ABPs) for treatment of a patient exposed to HBV, comprising:
- a. isolating single cells from a blood sample from a donor previously vaccinated with a Hepatitis B virus (HBV) vaccine;
- b. amplifying polynucleotides from the isolated single cells, wherein each polynucleotide encodes a cognate pair of heavy chain and light chain variable regions from a single cell by overlap extension reverse transcriptase polymerase chain reaction (OE-RT-PCR);
- c. cloning the polynucleotides obtained from the amplification into an expression vector, thereby obtaining polynucleotide constructs encoding recombinant antibodies;
- d. introducing the antibody expression constructs into a cell line;
- e. expressing antibodies from the antibody expression constructs in the cell line;
- and
- f. obtaining the ABPs.
59-77. (canceled)
82-83. (canceled)
86-111. (canceled)
Dependencies are inferred from the claim text.